^
Association details:
| Biomarker: | BRAF G469A |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.
Excerpt:
In addition to 3 pts with partial responses during escalation (11%), an additional 9 of 83 (11%) evaluable pts at expansion had a partial response:...1 with BRAF G469A head & neck cancer...The duration of response ranged from 2 to 24+ months.
DOI:
10.1200/JCO.2017.35.15_suppl.2508
Trial ID:
